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Abstract
Background: Although statin use has been associated with
reduced prostate cancer aggressiveness, the impact of race and
patient characteristics on this association is not well understood.
We examined the association between statin use and prostate
cancer aggressiveness in Caucasians (CA) and African Americans
(AA) and explored effect modification by health-seeking beha-
viors associated with statin use.
Methods: Of 1,930 cases from The North Carolina-Louisiana
Prostate Cancer Project, 344 (18%) were classified as aggressive
based on clinical criteria. Utilizing nonaggressive cases as referent,
logistic regression was used to examine the association between
statin use and prostate cancer aggressiveness, overall and stratified
by race. Smoking and prostate cancer screening were examined as
effect modifiers of this association.
Results: There was an inverse association between statin use
and prostate cancer aggressiveness [OR, 0.74; 95% confidence
interval (CI), 0.56–0.96], with comparable effect estimates in
both races. Although not statistically significant, statin use was
associated with reduced ORs for aggressive prostate cancer in
never-screened men (OR, 0.79; 95% CI, 0.45–1.39), men
screened at low/recommended frequency (once/year; OR,
0.66; 95% CI, 0.41–1.06), and men screened at high frequency
(>once/year; OR, 0.78; 95% CI, 0.53–1.15). Inverse associations
between statins and aggressive prostate cancer were strongest in
never smokers (OR, 0.42; 95% CI, 0.25–0.72), attenuated in
former smokers (OR, 0.84; 95% CI, 0.59–1.19), and absent in
current smokers (OR, 1.36; 95% CI, 0.70–2.64).
Conclusions: Statin use was associated with reduced prostate
cancer aggressiveness in CA and AAs, with strongest inverse
associations in nonsmokers.
Impact: Health-seeking behaviors associated with statin use
should be considered when examining the impact of statins on
prostate cancer aggressiveness. Cancer Epidemiol Biomarkers Prev; 25(4);
670–7. 2016 AACR.
Introduction
Prostate cancer is the most commonly diagnosed noncu-
taneous cancer type in U.S. males and the second most
common cause of male cancer-related deaths (1). Aggressive
disease characteristics at diagnosis, defined by biopsy Gleason
sum, clinical stage, and PSA level, are associated with
increased prostate cancer–specific mortality (2). As such, there
is a need to identify factors which may impact prostate cancer
aggressiveness.
Statins, a class of cholesterol-lowering drugs, are used by
approximately one in every four adult males in the U.S. pop-
ulation (3). Although statin use is not associated with overall
prostate cancer incidence (4–7), two meta-analyses have
reported an inverse association between statin use and the risk
of aggressive prostate cancer (5, 8). However, many of the
studies contributing to these meta-analyses were limited by
incomplete assessment of type and dose of statin and the use of
other cholesterol-lowering drugs, as well as patient character-
istics, including dietary cholesterol and saturated fat intake,
smoking status, and prostate cancer screening history. In addi-
tion, these prior studies were conducted in predominantly
Caucasian (CA) populations, and therefore the impact of race
on these associations is unknown.
Using the population-based North Carolina-Louisiana Pros-
tate Cancer Project (PCaP), we examined associations between
statin use, dose and type, and prostate cancer aggressiveness,
overall and stratified by race. We explored prostate cancer
screening frequency as both a confounder and an effect mod-
ifier of the association between statin use and prostate cancer
aggressiveness. In addition, we tested whether associations
differed by smoking status, given that smoking is a known
modifier of serum lipid levels.
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Materials and Methods
Study population
The PCaP is a population-based, case-only study of incident
prostate cancer in two southern U.S. states (NC and LA; ref. 9).
Men with the first diagnosis of histologically confirmed prostate
cancer on or after July 1, 2004, were eligible to participate in PCaP
if they were 40 to 79 years of age at diagnosis, could complete the
study interview in English, did not live in an institution or nursing
home, and were not cognitively impaired. Eligibility criteria also
required men to self-identify as either African American/black
(AA) or CA/white in response to an open-ended question "what is
your race?" Recruitment ended inOctober 2007 inNC and in July
2009 in LA. Research protocols were approved by the Institutional
review boards at the University of North Carolina (Chapel Hill,
NC), Louisiana State University Health Services Center, and
Department of Defense CaP Research Program.
Exposure assessment
PCaP nurses administered a series of structured questionnaires
that included baseline characteristics, prostate cancer screening
history, and diet and medications during an in-home visit con-
ducted approximately 3 months after diagnosis (9). Prostate
cancer screening was defined as having received more than one
PSA test and/or digital rectal exam (DRE) prior to 12 months
before diagnosis. Among screened men, screening frequency was
calculated as the total number of PSA or DRE in the patient's
lifetime divided by the number of years since the first PSA or DRE.
Screening was then classified as a 3-level variable (never screened,
1 PSA and/or DRE per year, >1 PSA and/or DRE per year). We
also generated this variable based upon PSA tests only, without
consideringDRE. Screening frequency cut-off points were selected
on the basis of prostate cancer screening guidelines in place at the
timeof PCaP recruitment, which recommended annual screening.
Screened men reporting <1 screening test per year were included
with screened men reporting the recommended 1 test per year,
given insufficient numbers to separate these two categories. The
dietary assessment instrument was a modified version of the
validated NCI Diet History Questionnaire (DHQ; refs. 10, 11)
to which numerous Southern U.S. foods were added. Men were
asked to report dietary intake during the 12-month period prior to
prostate cancer diagnosis. Dietary cholesterol intake (mg/day)
and the average percentage of calories obtained from saturated fat
were calculated using DietCalc Analysis Software [version 1.4.3,
NCI (Bethesda, MD), Applied Research Program, November
2005]. Although no gold standard exists for validating calories
from saturated fat and dietary cholesterol, a comparative valida-
tion study has been performed for the NCI DHQ, indicating that
energy-adjusted correlations between multiple 24-hour recalls
and DHQ estimates were 0.68 for saturated fat intake, 0.64 for
dietary cholesterol, and 0.66 for total fat (11). Study participants
gathered all prescription and nonprescription medications and
supplements used in the 2-week period prior to interview and
presented them to the nurse at the time of interview for docu-
mentationof currentmedicationuse, including type anddose. For
this analysis, we abstracted statin use [atorvastatin (Lipitor,
Caduet), simvastatin (Zocor, Vytorin), rosuvastatin (Crestor),
lovastatin (Altoprev, Advicor), pravastatin (Pravachol), and flu-
vastatin (Lescol)] and nonstatin cholesterol-lowering drug use
[niacin (Niaspan, Niacor), fibrate (gemfibrozil, Tricor), and eze-
timibe (ezetimibe, Vytorin)]. Statin type was classified as hydro-
philic (rosuvastatin and pravastatin) or lipophilic (atorvastatin,
simvastatin, lovastatin, and fluvastatin; ref. 12). Statin dose was
converted to a simvastatin dose equivalent, as described previ-
ously (13), and dichotomized as low/normal (20 mg simva-
statin dose equivalent) versus highdose (>20mg simvastatin dose
equivalent). Data regarding the duration of statin use were not
collected in this study.
Outcome assessment
Clinical stage, biopsy Gleason sum, and PSA at diagnosis were
abstracted from medical records. Prostate cancer aggressiveness
was defined using these three variables as follows: (i) high aggres-
sive (Gleason sum 8 or PSA > 20 ng/mLorGleason sum 7 and
clinical stage T3–T4), (ii) low aggressive (Gleason sum < 7 and
clinical stage T1–T2 and PSA < 10 ng/mL), and (iii) intermediate
aggressive (all other cases), as described previously for PCaP (9).
Our outcome of interest was high aggressive prostate cancer, and
low/intermediate aggressive disease was utilized as the referent
group for all analyses. Complete prostate cancer aggressiveness
data were missing for 85 men, and these men were excluded from
our analysis. We also excluded men who were missing body mass
index (BMI; n ¼ 21), smoking status (n ¼ 2), and prostate cancer
screening frequency (n¼ 220), resulting in 1,930 research subjects
(n ¼ 1,012 CA and n ¼ 918 AA) eligible for this analysis.
Statistical analysis
We examined differences in patient and tumor characteristics
between CA and AAmen, and between statin users and nonusers,
using c2 tests for categorical variables, Student t tests for contin-
uous, normally distributed variables, and rank sum tests for
continuous nonnormally distributed variables.
Logistic regression was used to estimate crude (age-adjusted)
and multivariable-adjusted ORs and 95% confidence intervals
(CI) for the association between statin use, dose and type, and
prostate cancer aggressiveness (high vs. low/intermediate). Given
that our outcomeofhigh aggressive prostate cancer does notfit the
rare disease assumption, ORs should not be interpreted as relative
risk ratios. Formultivariable analysis, weutilized adirected acyclic
graph to select covariates and thenperformed backwards selection
to build our final model, which included age (continuous), race
(AA vs. CA), site (NC vs. LA), BMI (continuous and log trans-
formed), cholesterol intake (continuous and log transformed),
percent calories from saturated fat (continuous), smoking status
(never, former, vs. current), and prostate cancer screening fre-
quency (never,1 screening test per year, vs. >1 screening test per
year). When examining associations between hydrophilic statins
and prostate cancer aggressiveness, we excluded lipophilic statin
users, and vice versa. We conducted a sensitivity analysis excluding
men who used nonstatin cholesterol-lowering drugs (22% of
statin users and 7% of statin nonusers). We also explored the
effect of additionally adjusting models for education level (less
than high school, high school graduate, vs. college graduate or
some college), annual household income (<$20,000, $20,000–
$50,000, $50,000–$80,000, vs. >$80,000), and family history of
prostate cancer in afirst-degree relative (yes vs. no) in the subset of
men for whom all of these data were available (n ¼ 1,634). To
examine smoking status and prostate cancer screening frequency
as potential effect modifiers of the association between statin use
and prostate cancer aggressiveness, we conducted stratified anal-
ysis by each of these health-seeking behaviors. We tested for
interaction between smoking status and statin use for predicting
prostate cancer aggressiveness by incorporating a cross-product
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term into the logistic regression model and calculating the global
P value of the interaction term using the Wald test.
Statistical analyses were performed using Stata 13.1 (Stata-
Corp). Statistical significance was two sided, with P < 0.05.
Results
Characteristics of study participants by race
Incident prostate cancer cases in this study included 1,012 CAs
(n ¼ 479 from NC and n ¼ 533 from LA) and 918 AAs (n ¼ 448
from NC and n¼ 470 from LA; Table 1). As presented in Table 1,
AAs were younger at diagnosis than CAs (62 vs. 64 years of age).
AAs had a higher median PSA level than CAs (6.2 vs. 5.2 ng/mL)
andweremore likely to have a high biopsy Gleason sum (4þ 3;
23% vs. 18%) and aggressive prostate cancer (21% vs. 15%).
AAs were less frequently screened for prostate cancer than CAs,
with 36% of AAs and 11% of CAs never undergoing any prostate
cancer screening (Table 1). In addition, AAs were less highly
educated, reported a lower annual household income, and were
more likely to be current smokers thanCAs (21%vs. 9%; Table 1).
Despite lower prevalence of cardiovascular disease (13% vs.
19%), AAs were more likely than CAs to have comorbid health
Table 1. Demographic and tumor characteristics of CA and AA prostate cancer cases in PCap
CA (n ¼ 1,012) AA (n ¼ 918) P
Age at diagnosis, mean (SD) 64 (8) 62 (8) <0.0001
Site
North Carolina 479 (47) 448 (49) 0.519
Louisiana 533 (53) 470 (51)
Clinical stage
T1 559 (55) 509 (55) 0.926
T2–T4 453 (45) 409 (45)
PSA (ng/mL), median (IQR) 5.2 (4.1–7.5) 6.2 (4.5–10.7) <0.0001
Biopsy Gleason sum
3þ4 829 (82) 702 (77) 0.006
4þ3 180 (18) 208 (23)
Aggressive prostate cancer
Low/intermediate 861 (85) 725 (79) <0.0001
High 151 (15) 193 (21)
Prostate cancer screening frequency
Never 116 (11) 328 (36) <0.0001
1 test per year 386 (38) 377 (75)
>1 test per year 510 (50) 123 (25)
Family history of prostate cancer (first-degree relative)a
No 706 (75) 608 (72) 0.122
Yes 232 (25) 236 (28)
Education
Less than high school 94 (9) 265 (29) <0.0001
High school graduate 212 (21) 258 (28)
College graduate or some college 706 (70) 394 (43)
Incomeb
<$20,000 91 (10) 273 (32) <0.0001
$20,000–$50,000 268 (29) 327 (39)
$50,000–$80,000 229 (25) 137 (16)
>$80,000 337 (36) 105 (12)
Smoking status
Never 367 (36) 283 (31) <0.0001
Former 551 (54) 441 (48)
Current 94 (9) 194 (21)
BMI (kg/m2)
<30 635 (63) 558 (61) 0.375
30 377 (37) 360 (39)
Charlson comorbidity index
0 542 (54) 436 (47) 0.008
1 470 (46) 482 (53)
Cardiovascular disease
No 821 (81) 791 (87) 0.001
Yes 187 (19) 118 (13)
Diabetes
No 842 (84) 674 (74) <0.0001
Yes 166 (16) 239 (26)
Dietary cholesterol intake (mg/day), median (IQR) 262 (180–355) 302 (206–439) <0.0001
Percent saturated fat intake, mean (SD) 11.2 (2.7) 10.0 (2.6) <0.0001
Nonstatin cholesterol-lowering drug use
None 842 (83) 844 (92) <0.0001
Niacin/fibrate/ezetimibe 170 (17) 74 (8)
Abbreviation: IQR, interquartile range.
aFamily history was missing for 74 CA and 74 AA men.
bIncome was missing for 12 CA and 31 AA men, whereas 75 CA and 45 AA men refused to answer this question.
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conditions (Charlson index  1; 53% vs. 46%), including dia-
betes (26% vs. 16%). Finally, AAs had higher dietary cholesterol
intake (302 vs. 262 mg/day), although the percentage of calories
from saturated fat was higher in CAs (11.2% vs. 10.0%; Table 1).
Characteristics of study participants by statin use
Of a total of 1,930 patients, 725 (38%) were statin users at the
time of interview, with the majority of statin users taking either
simvastatin (38%) or atorvastatin (34%) and the remainder using
rosuvastatin (10%), pravastatin (9%), lovastatin (5%), or fluvas-
tatin (2%). There were no significant differences in statin type or
dose by race (data not shown). As shown in Table 2, statin users
were older than nonusers (65 vs. 62 years of age at diagnosis)
and were more likely to be CA (56% vs. 44%). Although there
were no significant differences in biopsy Gleason sum or clinical
stage by statin use, statin users had lowermedian PSA level (5.3 vs.
Table 2. Demographic and tumor characteristics of statin users and nonusers in PCaP
Statin nonusers
(n ¼ 1,205)
Statin users
(n ¼ 725) P
Age at diagnosis, mean (SD) 62 (8) 65 (7) <0.0001
Race
CA 604 (50) 408 (56) 0.009
AA 601 (50) 317 (44)
Site
North Carolina 602 (50) 325 (45) 0.029
Louisiana 603 (50) 400 (55)
Clinical stage
T1 679 (56) 389 (54) 0.249
T2–T4 526 (44) 336 (46)
PSA, median (IQR) 5.8 (4.3–9.8) 5.3 (4.1–7.6) <0.0001
Biopsy Gleason sum
3 þ 4 941 (79) 590 (82) 0.101
4 þ 3 256 (21) 132 (18)
Aggressive prostate cancer
Low/intermediate 972 (81) 614 (85) 0.025
High 233 (19) 111 (15)
Prostate cancer screening frequency
Never 278 (23) 82 (11) <0.0001
1 Test per year 365 (30) 260 (36)
>1 Test per year 562 (47) 383 (53)
Family history of prostate cancer (first-degree relative)a
No 811 (73) 503 (75) 0.214
Yes 304 (27) 164 (25)
Education
Less than high school 234 (19) 125 (17) 0.320
High school graduate 299 (25) 171 (24)
College graduate or some college 672 (56) 428 (59)
Incomeb
<$20,000 238 (22) 126 (19) 0.331
$20,000–$50,000 361 (33) 234 (35)
$50,000–$80,000 221 (20) 145 (22)
>$80,000 284 (25) 158 (24)
Smoking status
Never 407 (34) 243 (34) <0.0001
Former 585 (49) 407 (56)
Current 213 (18) 75 (10)
BMI (kg/m2)
<30 793 (66) 400 (55) <0.0001
30 412 (34) 325 (45)
Charlson comorbidity index
0 697 (58) 281 (39) <0.0001
1 508 (42) 444 (61)
Cardiovascular disease
No 1,104 (92) 508 (71) <0.0001
Yes 95 (8) 210 (29)
Diabetes
No 1,022 (85) 494 (69) <0.0001
Yes 179 (15) 226 (31)
Dietary cholesterol intake (mg/day) 288 (198–406) 269 (179–368) 0.0001
Percent saturated fat intake, mean (SD) 10.6 (2.7) 10.7 (2.7) 0.811
Nonstatin cholesterol-lowering drug use
None 1,123 (93) 563 (78) <0.0001
Niacin/fibrate/ezetimibe 82 (7) 162 (22)
Abbreviation: IQR, interquartile range.
aFamily history missing for 90 statin nonusers and 58 statin users.
bIncome was missing for 27 statin nonusers and 16 statin users, whereas 74 statin nonusers and 46 statin users refused to answer this question.
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5.8 ng/mL) and a lower frequency of aggressive prostate cancer
(15% vs. 19%).
Statin users were more frequently screened for prostate cancer,
relative to nonusers (Table 2). Statin users had similar level of
education and annual household income as nonusers but were
less likely to be current smokers (10% vs. 18%; Table 2). Relative
to nonusers, statin users were more likely to be obese (44% vs.
34%) and have a comorbid condition (Charlson index  1; 61%
vs. 42%), including diabetes (31% vs. 15%) and cardiovascular
disease (29% vs. 8%; Table 2). However, statin users had lower
dietary cholesterol intake (269 vs. 288 mg/day), although there
was no difference in saturated fat intake between statin users and
nonusers.
We also examined differences in statin users versus nonusers
stratified by race and found that these aforementioned differences
in tumor and patient characteristics between statin users and
nonusers were observed in both CAs and AAs (Supplementary
Table S1).
Associations between statin use and prostate cancer
aggressiveness
Of 344 (18%) incident cases of high aggressive prostate cancer,
111 (32%) occurred in statin users and 233 (68%) occurred in
nonusers. For comparison, of 1,586 (82%) incident cases of
nonaggressive prostate cancer, 614 (39%) occurred in statin users
and 972 (61%) occurred in nonusers. Utilizing nonaggressive
cases as the referent group, and adjusting for potential confoun-
ders, statin use was associated with a significantly reduced OR for
aggressive prostate cancer (OR, 0.74; 95%CI, 0.56–0.96; Table 3),
with similar effect estimates inCAs (OR, 0.64; 95%CI, 0.44–0.95)
and AAs (OR, 0.84; 95%CI, 0.58–1.21), although the association
inAAswasnot statistically significant.Weobserved similar inverse
associations in men taking a low/normal statin dose (OR, 0.70;
95% CI, 0.49–1.01) and in men taking a high statin dose (OR,
0.76; 95% CI, 0.58–1.04), with no evidence for a dose–response
relationship, although small numbers of men in each dose
category may limit our power to detect such a relationship.
Finally, although there was a suggestion of a stronger protective
effect with hydrophilic relative to lipophilic statins (OR, 0.56;
95% CI, 0.32–0.99 and OR, 0.77; 95% CI, 0.58–1.02, respective-
ly), these estimateswere somewhat imprecise due to lownumbers
of men using hydrophilic statins and should be interpreted
cautiously. Excluding men using nonstatin cholesterol-lowering
drugs or additionally adjusting our models for education level,
annual household income, and family history of prostate cancer
did not substantially alter our findings (Supplementary Tables S2
and S3, respectively).
Impact of health-seeking behaviors on the association between
statin use and prostate cancer aggressiveness
To explore possible prostate cancer screening–related detec-
tion biases, we examined prostate cancer screening frequency as
an effect modifier of the association between statin use and
prostate cancer aggressiveness. We observed nonstatistically
significant inverse associations between statin use and prostate
cancer aggressiveness in men who had never undergone PSA or
DRE screening (OR, 0.79; 95% CI, 0.45–1.39), in men who
were screened annually or less frequently (OR, 0.66; 95% CI,
0.41–1.06), and in men who were screened more frequently
than once a year (OR, 0.78; 95% CI, 0.53–1.15; Table 4),
although these findings should be interpreted cautiously, given
relatively small numbers in each screening category. We
observed similar findings when we classified prostate cancer
screening as PSA tests only, without considering DRE (data not
shown).
Smoking increases low-density and total cholesterol levels and
decreases high-density cholesterol levels (14, 15), potentially
offsetting the cholesterol-lowering effect of statin use. We found
no association between statin use and prostate cancer aggres-
siveness in current smokers (OR, 1.36; 95% CI, 0.70–2.64). In
contrast, there was a strong inverse association between statin use
and prostate cancer aggressiveness in never smokers (OR, 0.42;
95%CI, 0.25–0.72),with an attenuated protective effect in former
smokers (OR, 0.84; 95% CI, 0.59–1.19; Table 5) and a significant
Table 3. Associations between statin use, dose and type, and prostate cancer aggressiveness, overall and stratified by race
All CA AA
n, cases
(aggressive) ORa (95% CI) ORb (95% CI)
n, cases
(aggressive) ORa (95% CI) ORb (95% CI)
n, cases
(aggressive) ORa (95% CI) ORb (95% CI)
Statin use
No use 1,205 (233) 1.00 (ref) 1.00 (ref) 604 (99) 1.00 (ref) 1.00 (ref) 601 (134) 1.00 (ref) 1.00 (ref)
Use 725 (111) 0.68
(0.53–0.87)
0.74
(0.56–0.96)
408 (52) 0.65
(0.45–0.93)
0.64
(0.44–0.95)
317 (59) 0.73
(0.51–1.03)
0.84
(0.58–1.21)
Statin dosec
No use 1,205 (233) 1.00 (ref) 1.00 (ref) 604 (99) 1.00 (ref) 1.00 (ref) 601 (134) 1.00 (ref) 1.00 (ref)
Low/normal 306 (45) 0.65
(0.45–0.92)
0.70
(0.49–1.01)
180 (24) 0.68
(0.42–1.11)
0.66
(0.40–1.09)
126 (21) 0.64
(0.38–1.06)
0.74
(0.43–1.26)
High 419 (66) 0.70
(0.52–0.95)
0.76
(0.55–1.04)
228 (28) 0.62
(0.39–0.98)
0.63
(0.39–1.01)
191 (38) 0.79
(0.53–1.19)
0.90
(0.59–1.38)
Statin typed
No use 1,205 (233) 1.00 (ref) 1.00 (ref) 604 (99) 1.00 (ref) 1.00 (ref) 601 (134) 1.00 (ref) 1.00 (ref)
Hydrophilic 132 (16) 0.53
(0.31–0.91)
0.56
(0.32–0.99)
81 (8) 0.48
(0.22–1.05)
0.45
(0.20–1.00)
51 (8) 0.62
(0.29–1.36)
0.72
(0.32–1.62)
Lipophilic 591 (94) 0.71 (0.54–0.92) 0.77
(0.58–1.02)
327 (44) 0.69
(0.46–1.02)
0.69
(0.46–1.04)
264 (50) 0.74
(0.51–1.07)
0.86
(0.58–1.27)
aAdjusted for age only.
bAdjusted for age, race (except for analyses stratified by race), site, BMI, cholesterol intake, percent saturated fat intake, smoking status, and prostate cancer
screening frequency.
cLow/normal dose 20 mg simvastatin or equivalent; high dose > 20 mg simvastatin or equivalent.
dHydrophilic ¼ rosuvastatin and pravastatin; lipophilic ¼ atorvastatin, simvastatin, lovastatin, and fluvastatin.
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interaction between smoking status and statin use in predicting
prostate cancer aggressiveness (Wald test; P ¼ 0.0008).
Discussion
Using data from the population-based PCaP study, we report
an inverse association between statin use and prostate cancer
aggressiveness. We observed a similar magnitude of association
between statin use and prostate cancer aggressiveness in both CAs
and AAs; findings were supported by a prior study, which found
that associations between statin use and risk of high-grade pros-
tate cancer did not vary by race (16). In contrast to prior cohort
and case–control analyses of statin use and prostate cancer risk
using prostate cancer–freemen as the referent group (5, 8, 16), the
case-only designof this study examined the impact of statin useon
disease aggressiveness among men diagnosed with prostate can-
cer. However, our results are in agreement with approximately
20% to 25% reduced risk of aggressive prostate cancer in statin
users, relative tononusers reportedby twometa-analyses (5, 8). As
such, our findings strengthen existing rationale to explore a role
for statins in aggressive prostate cancer prevention.
One important consideration when studying the impact of
statin use on prostate cancer aggressiveness is that detection bias
arising from higher rates of prostate cancer screening in statin
users could produce an inverse association with aggressive dis-
ease, irrespective of a causal relationship (17, 18). In this study,we
found that adjusting our models for prostate cancer screening
frequency did not substantially impact our estimates. Further-
more, analyses stratified by screening frequency showed a similar
magnitude of inverse association between statin use and prostate
cancer aggressiveness in men screened at high frequency (i.e.,
more than once a year), low, or recommended frequency (i.e.,
annually or less) and in unscreened men, suggesting that the
association between statin use and prostate cancer aggressiveness
cannot be completely explained by screening-related detection
bias. In support of these findings, inverse associations between
statin use and aggressive prostate cancer have been reported both
in Europeanpopulationswith very low screening rates (19) and in
U.S. populations with higher screening rates (20), although a
secondary analysis of the Prostate Cancer Prevention Trial, where-
in all participantswere screened annually, reported no association
between statin use andhigh-grade prostate cancer (21).Moreover,
an analysis of simulated datasets with different PSA screening
frequencies suggested that detection bias is unlikely to explain the
association between statin use and reduced prostate cancer aggres-
siveness (18). Yet another factor to consider is that statin use
lowers PSA levels by approximately 3% to 4% (22, 23), poten-
tially reducing the likelihood of prostate biopsy and aggressive
prostate cancer diagnosis. Indeed, we observed that statin users
had lower PSA levels than nonusers in this study. Randomized
trials conducting PSA-independent biopsies at regular intervals
may circumvent this potential source of detection bias, and
secondary analysis of one such trial reported a null association
between statin use and high-grade prostate cancer (24). However,
given that trial participants are selected based upon specific
eligibility criteria and do not represent a population-based sam-
ple, findings from secondary analyses of trials (21, 24) may differ
from findings reported by population-based studies (19, 20),
including our own. As such, although the potential for screen-
ing-related detection biases should be considered, our findings, in
addition to those from populations with different PSA screening
frequencies (25), support a true association between statin use
and prostate cancer aggressiveness.
In addition to differences in prostate cancer screening beha-
viors, characteristics of statin users differ from thoseof nonusers in
a variety of ways. Data from this study show that obesity and
diabetes, both associated with increased prostate cancer–specific
mortality (26, 27), were more prevalent among statin users. On
the other hand, we observed that statin use was associated with
health-seeking behaviors, as indicated by the higher prevalence of
prostate cancer screening, lower prevalence of smoking, and
reduced dietary cholesterol intake, relative to nonusers. These
health-seeking behaviors themselves have been associated with
reduced risk of aggressive prostate cancer (17, 28–33), potentially
giving rise to a "healthy-user" bias, whereby the association
between statin use and prostate cancer aggressiveness could be
explained by the health-seeking behaviors of statin users, and not
statin use per se (34). In this analysis, we found that adjusting our
models for these health-seeking behaviors did not substantially
impact our estimates. However, analyses stratified on smoking
status revealed a strong inverse association between statin use and
prostate cancer aggressiveness in never smokers, a slightly atten-
uated effect in former smokers, and no association in current
smokers. There may be multiple mechanisms contributing to the
observed effectmodification by smoking status, one ofwhichmay
be the association between smoking and prostate cancer aggres-
siveness (32, 33). However, given that the impact of statins on
prostate cancer may be mediated, at least in part, via their
cholesterol-lowering properties (35), a smoking-related increase
in cholesterol level (14, 15) could potentially offset the protective
effect of statins on prostate cancer aggressiveness. If confirmed in
Table 4. Associations between statin use and prostate cancer aggressiveness,
stratified by prostate cancer screening frequency
n, cases
(aggressive) ORa (95% CI) ORb (95% CI)
Never screened
Statin nonusers 278 (87) 1.00 (ref) 1.00 (ref)
Statin users 82 (23) 0.81 (0.47–1.41) 0.79 (0.45–1.39)
 1 Screening tests per year
Statin nonusers 365 (61) 1.00 (ref) 1.00 (ref)
Statin users 260 (35) 0.67 (0.42–1.07) 0.66 (0.41–1.06)
> 1 Screening tests per year
Statin nonusers 562 (85) 1.00 (ref) 1.00 (ref)
Statin users 383 (53) 0.79 (0.54–1.15) 0.78 (0.53–1.15)
aAdjusted for age only.
bAdjusted for age, race, site, BMI, cholesterol intake, percent saturated fat intake,
and smoking status.
Table 5. Associations between statin use and prostate cancer aggressiveness,
stratified by smoking status
n, cases
(aggressive) ORa (95% CI) ORb (95% CI)
Never smokers
Statin nonusers 407 (69) 1.00 (ref) 1.00 (ref)
Statin users 243 (24) 0.43 (0.26–0.72) 0.42 (0.25–0.72)
Former smokers
Statin nonusers 585 (109) 1.00 (ref) 1.00 (ref)
Statin users 407 (67) 0.78 (0.56–1.10) 0.84 (0.59–1.19)
Current smokers
Statin nonusers 213 (55) 1.00 (ref) 1.00 (ref)
Statin users 75 (20) 1.04 (0.57–1.90) 1.36 (0.70–2.64)
aAdjusted for age only.
bAdjusted for age, race, site, BMI, cholesterol intake, percent saturated fat intake,
and prostate cancer screening frequency.
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future studies, these hypothesis-generating findings may add to
the many established reasons to promote smoking cessation for
direct and indirect reduction of a myriad of noncommunicable
diseases.
Our findings should be considered in light of the strengths and
limitations of this study. First, statin use was captured at the time
of interview, with no information regarding the timing of statin
initiation relative to prostate cancer diagnosis. However, given
that themajority of our study population was interacting with the
health care system prior to prostate cancer diagnosis (75% of
individuals had a history of PSA screening), it is likely that men
indicated for statin therapy would have initiated statins before
diagnosis. Indeed, a previous study reported similar prevalence of
statin use before (29%) and after (30%)prostate cancer diagnosis,
during a study period (1998–2009) which overlapped that of this
study (2004–2009; ref. 36). Moreover, any potential misclassifi-
cation of unexposed individuals (i.e., prediagnosis nonusers who
initiated statin use after diagnosis) as exposed individuals (i.e.,
prediagnosis statin users) would likely bias our estimates towards
the null. As such, our studymay have underestimated the strength
of the association between prediagnosis statin use and prostate
cancer aggressiveness. In addition, although we did not have
access to data for duration of use or adherence to statin therapy,
the type and dose of statin and nonstatin cholesterol-lowering
drugs were documented by a trained nurse, thus improving the
accuracy of our exposure data. Second, although serum choles-
terol measurements were unavailable, dietary cholesterol and
saturated fat intake were available for all study participants, and
saturated fat intake is an important determinant of serum cho-
lesterol level (37). Third, we lacked sufficient numbers to separate
men reporting annual prostate cancer screening frommen report-
ing less-than-annual screening, and larger studies should explore
associations between statins and prostate cancer aggressiveness
within each of these categories. Fourth, our study had somewhat
limited statistical power to conduct analyses stratified by health-
seeking behaviors, and larger studies are required to further
explore these hypotheses. Finally, observational studies examin-
ing the association between statin use and prostate cancer are
susceptible to confounding by indication, given that statin use is
not randomized. However, an important strength of this study is
our comprehensive assessment of clinical and demographic char-
acteristics, in addition to health-seeking behaviors of statin users
and nonusers, and adjustment for these potential confounders in
our analysis.
In summary, we report an inverse association between statin
use and aggressive prostate cancer in both CAs and AAs. Differ-
ences in patient characteristics and health-seeking behaviors by
statin use should be an important consideration for future obser-
vational studies of statin use and prostate cancer, although our
findings suggest that the detection bias arising fromhigher rates of
prostate cancer screening in statin users does not entirely explain
the inverse association between statin use and prostate cancer
aggressiveness. The stronger protective effect of statin use in
nonsmokers requires confirmation in other studies but may add
to existing rationale, supporting efforts to reduce smoking rates in
the population. Statins are cost-effective and widely prescribed
cholesterol-lowering drugs, and recent cholesterol-lowering
guidelines (38) will likely further increase the prevalence of statin
use. Given that cardiovascular disease and cancer are the twomost
common causes of mortality in the United States (39), with
prostate cancer the second most common cause of cancer-related
death in U.S. men (1), understanding the role of statins in
aggressive prostate cancer prevention will have important public
health impact.
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